Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219920 | 1.00 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL24284431 | 0.95 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL19222762 | 0.95 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL22355739 | 0.94 | HCRTR2 (0.89) | HCRTR2 | |
| SCHEMBL22346089 | 0.94 | HCRTR2 (0.89) | HCRTR2 | |
| SCHEMBL19220023 | 0.93 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL19220005 | 0.93 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL19222990 | 0.91 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL19222829 | 0.90 | HCRTR2 (1.00) | HCRTR2 | |
| SCHEMBL19222776 | 0.90 | HCRTR2 (1.00) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12281073-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20240174610-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| US-11292766-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220081399-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-17 | — | — | US | disclosed |
| US-20200115399-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20190263843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-10287305-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20190031611-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20170226137-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170226137-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081399-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-20240174610-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-20190263843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-12281073-B2 | Substituted piperidine compound and use thereof | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-11292766-B2 | Substituted piperidine compound and use thereof | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | HCRTR2 1/4885 |
| US-20170226137-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-20200115399-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-20190031611-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-10287305-B2 | Substituted piperidine compound and use thereof | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.